Full-Time
Develops gene-editing therapies using CRISPR
$260k - $290k/yr
Boston, MA, USA
Hybrid
Three days on-site per week required.
| , |
CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 to treat serious diseases. It edits genes in human cells, either ex vivo or in vivo, to correct disease-causing mutations, focusing on sickle cell disease, cancer, and other genetically defined conditions. The company supports its pipeline through partnerships and licensing in addition to internal R&D and clinical work, rather than relying solely on in-house development. Its goal is to deliver durable, disease-modifying therapies that meet unmet medical needs for patients worldwide through a global biopharmaceutical strategy.
Company Size
201-500
Company Stage
IPO
Headquarters
Switzerland
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
People at CRISPR Therapeutics who can refer or advise you
Health Insurance
Dental Insurance
Vision Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Flexible Work Hours
Hybrid Work Options
Stock Options
401(k) Retirement Plan
Wellness Program
Mental Health Support
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Conference Attendance Budget
Professional Development Budget
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Parental Leave
Paid Vacation
Paid Holidays
Relocation Assistance
Sabbatical Leave
Paid Sick Leave
Employee Discounts
Employee Referral Bonus
Tuition Reimbursement
Professional Certification Support
Mentorship Program
Training Programs
Meal Benefits
Commuter Benefits
Legal Services
Research Collaboration Benefits
CRISPR Therapeutics to present at the Bank of America Securities 2026 Global Healthcare Conference. ZUG, Switzerland and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) - CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026 1:40 p.m. PDT. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation. About CRISPR Therapeutics CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY(R)(exagamglogene autotemcel [exa-cel]), the world's first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase(TM) editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
- **Funding Details**: CRISPR completed a private offering of convertible senior notes, raising net proceeds of $585.2 million, which, while intended ...
CRISPR Therapeutics has reported strong commercial progress for its gene therapy CASGEVY, with patient initiations nearly tripling year over year. The company plans to submit a regulatory application in the first half of 2026 to expand CASGEVY's approval to paediatric patients. The company's cardiovascular candidate CTX310 showed positive early clinical data, published in the New England Journal of Medicine, and is advancing into Phase 1b trials. CASGEVY is already commercially available, marking the company's transition from development to approved therapy. Despite the clinical progress, CRISPR Therapeutics remains unprofitable with a net loss of $581.6 million and limited revenue of approximately $3.5 million. The share price trades around 44% below analyst consensus targets, reflecting ongoing execution risk around trials and regulatory approvals.
CRISPR Therapeutics reported $116 million in revenue for fiscal year 2025, driven by its gene-editing therapy CASGEVY. The company generated $54 million in Q4 alone, with patient initiations increasing nearly threefold year-on-year. To date, 147 patients have begun treatment for sickle cell disease or beta thalassemia, supported by expanded reimbursement access across the US, Europe and the Middle East. The company is advancing its in vivo liver editing portfolio, including CTX310 for cardiovascular conditions and CTX460 for alpha-1 antitrypsin deficiency, expected to enter clinical trials mid-2026. CRISPR is also collaborating with Sirius Therapeutics on thromboembolic disease treatments, with Phase 2 data for its lead Factor XI candidate anticipated in the second half of 2026.
CRISPR Therapeutics has announced a $350 million offering of convertible senior notes to fund general corporate purposes, including pipeline development and commercialisation efforts. The gene editing therapy company currently trades at $52.80, approximately 38% below analysts' consensus target of $84.78. The convertible debt offering provides capital without immediate equity dilution, though conversion terms could affect the company's current 96 million share count. CRISPR Therapeutics generated only $4 million in revenue whilst posting ongoing losses, raising concerns about potential future dilution if pipeline development does not progress as planned. The company's shares have shown recent momentum with an 8.3% gain over 30 days. According to Simply Wall St's valuation model, shares trade 72.2% below estimated fair value.